靶向调控因子 MYC 对胰腺导管腺癌进行解构
Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.
机构信息
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon.
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
出版信息
Cancer Discov. 2020 Apr;10(4):495-497. doi: 10.1158/2159-8290.CD-20-0046.
Abstract
In this issue of , Sodir and colleagues employ a pancreatic ductal adenocarcinoma mouse model with mutant KRAS and inducible MYC to demonstrate that MYC acts as a reversible driver of malignant tumor progression. Abrogation of MYC triggers rapid regression and disassembly of the ensemble tumor through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms, providing a compelling rationale for therapeutic targeting of MYC..
摘要
本期杂志中，Sodir 及其同事采用带有突变 KRAS 和可诱导 MYC 的胰腺导管腺癌小鼠模型，证明 MYC 是恶性肿瘤进展的一种可逆驱动因素。通过内在和外在的肿瘤细胞机制，消除 MYC 会触发肿瘤的快速消退和分解，为 MYC 的治疗靶向提供了强有力的依据。
相似文献
1
Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.靶向调控因子 MYC 对胰腺导管腺癌进行解构
Cancer Discov. 2020 Apr;10(4):495-497. doi: 10.1158/2159-8290.CD-20-0046.
2
Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.抗 Myc 药物对小鼠胰腺癌的治疗作用。
J Natl Cancer Inst. 2014 Oct 11;106(12). doi: 10.1093/jnci/dju320. Print 2014 Dec.
3
Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting.胰腺癌中Brca2缺陷与Trp53失调：对治疗靶点的影响
Cancer Biol Ther. 2011 Jun 1;11(11):969-73. doi: 10.4161/cbt.11.11.16573.
4
Concepts to Target MYC in Pancreatic Cancer.针对胰腺癌中MYC的概念。
Mol Cancer Ther. 2016 Aug;15(8):1792-8. doi: 10.1158/1535-7163.MCT-16-0050. Epub 2016 Jul 12.
5
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.致癌性 ERBB2 异常和 KRAS 突变协同促进胰腺导管腺癌的进展。
Carcinogenesis. 2020 Mar 13;41(1):44-55. doi: 10.1093/carcin/bgz086.
6
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.一种用于KRAS突变胰腺癌细胞的MEK/PI3K/HDAC抑制剂联合疗法。
Oncotarget. 2015 Jun 30;6(18):15814-27. doi: 10.18632/oncotarget.4538.
7
Pancreatic cancer is suppressed by fibroblast-derived collagen I.胰腺癌受成纤维细胞衍生的胶原 I 抑制。
Cancer Cell. 2021 Apr 12;39(4):451-453. doi: 10.1016/j.ccell.2021.02.017. Epub 2021 Mar 11.
8
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.针对胆囊收缩素 2 受体的胰腺癌化学预防。
Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.
9
MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.miR-143-3p 通过靶向 KRAS 抑制胰腺导管腺癌的肿瘤发生。
Biomed Pharmacother. 2019 Nov;119:109424. doi: 10.1016/j.biopha.2019.109424. Epub 2019 Sep 12.
10
FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.FBP1 缺失通过削弱胰腺导管腺癌中的 c-Myc 表达导致 BET 抑制剂耐药。
J Exp Clin Cancer Res. 2018 Sep 10;37(1):224. doi: 10.1186/s13046-018-0888-y.
引用本文的文献
1
Beyond the Limit: MYC Mediates Tumor Immune Escape.突破极限：MYC介导肿瘤免疫逃逸。
Pharmaceuticals (Basel). 2025 Jun 29;18(7):978. doi: 10.3390/ph18070978.
2
Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma.与胰腺导管腺癌预后及肿瘤浸润免疫细胞相关的溶质载体家族基因的鉴定
Ann Transl Med. 2022 Jan;10(2):57. doi: 10.21037/atm-21-6341.
3
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer .靶向缺氧诱导因子1α的VHH212纳米抗体抑制胰腺癌血管生成并增强吉西他滨治疗效果
Cancer Biol Med. 2021 Apr 8;18(3):772-87. doi: 10.20892/j.issn.2095-3941.2020.0568.
4
Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.缺氧：胰腺癌药物递送的朋友还是敌人。
Cancer Lett. 2020 Nov 1;492:63-70. doi: 10.1016/j.canlet.2020.07.041. Epub 2020 Aug 18.
本文引用的文献
1
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype.MYC 指导并维持胰腺导管腺癌的表型。
Cancer Discov. 2020 Apr;10(4):588-607. doi: 10.1158/2159-8290.CD-19-0435. Epub 2020 Jan 15.
2
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.临床 KRAS(G12C) 抑制剂 AMG 510 可引发抗肿瘤免疫。
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
3
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.肿瘤细胞内在因素是免疫细胞浸润异质性和免疫治疗反应的基础。
Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26.
4
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.Myc通过调控炎症和免疫抑制与Ras协同作用。
Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.
5
MYC: Master Regulator of Immune Privilege.MYC：免疫豁免的主要调节因子。
Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. Epub 2017 Feb 21.
6
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.KRAS 突变型胰腺癌中 ERK 的长期抑制与 MYC 降解及衰老样生长抑制相关。
Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.
7
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles.致癌基因 MYC 的激活和抑制作用塑造了肿瘤特异性基因表达谱。
Nature. 2014 Jul 24;511(7510):483-7. doi: 10.1038/nature13473. Epub 2014 Jul 9.
8
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.耗竭癌相关成纤维细胞和纤维化会诱导免疫抑制，并加速胰腺癌发展，降低患者生存率。
Cancer Cell. 2014 Jun 16;25(6):719-34. doi: 10.1016/j.ccr.2014.04.005. Epub 2014 May 22.
9
MYC degradation.MYC 降解。
Cold Spring Harb Perspect Med. 2014 Mar 1;4(3):a014365. doi: 10.1101/cshperspect.a014365.
10
Modelling Myc inhibition as a cancer therapy.将Myc抑制作为一种癌症治疗方法进行建模。
Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.
Zotero 插件